{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab%2C&page=2", "query": { "intervention": "Ranibizumab,", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 262, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab%2C&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab%2C&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T04:35:49.117Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02140151", "title": "Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Age-related Macular Degeneration" ], "interventions": [ { "name": "Ranibizumab 0.5mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Southern California Desert Retina Consultants, MC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 108, "start_date": "2014-09-17", "completion_date": "2020-07-09", "has_results": false, "last_update_posted_date": "2022-08-25", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 4, "location_summary": "Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more", "locations": [ { "city": "Mountain View", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rapid City", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02140151" }, { "nct_id": "NCT01198327", "title": "Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Retinal Vein Occlusion" ], "interventions": [ { "name": "ranibizumab", "type": "DRUG" }, { "name": "Peripheral Laser", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Peter A Campochiaro, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-08", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 6, "location_summary": "Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Sacremento", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01198327" }, { "nct_id": "NCT04757610", "title": "OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "2.0 mg OPT-302", "type": "BIOLOGICAL" }, { "name": "0.5 mg ranibizumab", "type": "BIOLOGICAL" }, { "name": "Sham", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Opthea Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 986, "start_date": "2021-03-12", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 76, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04757610" }, { "nct_id": "NCT02471651", "title": "Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Dexamethasone intravitreal implant (0.7 mg)", "type": "DRUG" }, { "name": "Intravitreal anti-VEGF injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Retina Consultants", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-06", "completion_date": "2018-10-24", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 4, "location_summary": "Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02471651" }, { "nct_id": "NCT02387957", "title": "A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Fovista®", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 63, "start_date": "2016-04-26", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "New London", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387957" }, { "nct_id": "NCT01077401", "title": "Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2010-02", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 13, "location_summary": "Beverly Hills, California • La Jolla, California • Los Angeles, California + 10 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01077401" }, { "nct_id": "NCT00407381", "title": "The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Laser photocoagulation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2006-12", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2017-03-31", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00407381" }, { "nct_id": "NCT03059277", "title": "Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Intravitreal Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Southeast Clinical Research Associates, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-06-01", "completion_date": "2020-09-30", "has_results": false, "last_update_posted_date": "2018-06-14", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 2, "location_summary": "Charlotte, North Carolina • Statesville, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Statesville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03059277" }, { "nct_id": "NCT02511613", "title": "Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Squalamine Lactate Ophthalmic Solution, 0.2%", "type": "DRUG" }, { "name": "Placebo Ophthalmic Solution", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohr Pharmaceutical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 0, "start_date": "2015-07", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2017-04-27", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 4, "location_summary": "Beverly Hills, California • Hagerstown, Maryland • New York, New York + 1 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Hagerstown", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511613" }, { "nct_id": "NCT04704921", "title": "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "AMD", "nAMD", "Wet Age-related Macular Degeneration", "wAMD", "Wet AMD", "CNV", "Neovascular AMD", "Neovascular Age-related Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "ABBV-RGX-314", "type": "GENETIC" }, { "name": "Ranibizumab (LUCENTIS®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 671, "start_date": "2020-12-29", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-10-03T04:35:49.117Z", "location_count": 89, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704921" } ] }